ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "treatment and ultrasound"

  • Abstract Number: 411 • 2017 ACR/ARHP Annual Meeting

    Factors That Drive Treatment Recommendation during Rheumatoid Arthritis Patient´s Follow-up, Differ According to Physician Experience

    César Sifuentes-Cantú1, Irazu Contreras-Yañez2, Lina Saldarriaga Rivera3, Ana Cecilia Lozada4, Marwin Gutierrez5 and Virginia Pascual-Ramos1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 3Instituto Nacional de Rehabilitación, Mexico, Mexico, 4Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, 5Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico

    Background/Purpose: The management plan for rheumatoid arthritis (RA) might be a relatively simple task if only disease activity is considered but might become more complex…
  • Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting

    Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis

    Veena K. Ranganath1, David Elashoff2, Jenny Brook3, Ami Ben-Artzi4, Geraldine Navarro5, Lynnette Avedikian-Tatosyan6, George Karpouzas7, William Martin5, Tanaz A. Kermani5, Soo Choi5 and Gurjit S. Kaeley8, 1Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, 2David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, 3Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, 4Medicine, Cedars, Beverly Hills, CA, 5Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, 6Healthcare Partners, Los Angeles, CA, 7Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, 8Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL

    Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
  • Abstract Number: 2013 • 2017 ACR/ARHP Annual Meeting

    Physician Experience and Patient´s Disease Activity Affect the Impact of Musculoskeletal Ultrasound on the Treatment Decision in Rheumatoid Arthritis Patients

    César Sifuentes-Cantú1, Irazu Contreras-Yañez2, Marwin Gutierrez3 and Virginia Pascual-Ramos4, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 3Rheumatology, Instituto Nacional de Rehabilitación, Mexico City, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: In a real clinical setting of RA outpatients, we previously showed that musculoskeletal ultrasound (MUS) added to clinical evaluation impacted the treatment decision in…
  • Abstract Number: 2967 • 2017 ACR/ARHP Annual Meeting

    Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort

    Alexandre Sepriano1, Sofia Ramiro2, Robert B.M. Landewé3, Désirée van der Heijde1, Sarah Ohrndorf4, Oliver FitzGerald5, Marina Backhaus6, Maggie Larche7, Joanne Homik8, Alain Saraux9, Hilde B. Hammer10, Lene Terslev11, Mikkel Østergaard11, Gerd R. Burmester12, Bernard Combe13, Maxime Dougados14, Carol A Hitchon15, Gilles Boire16, Robert G. Lambert8, Rana Dadashova17, Joel Paschke18, Edna Hutchings17 and Walter P. Maksymowych17, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 3University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, 4Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, 5ASRI, Dublin, Ireland, Dublin, Ireland, 6Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, 7Medicine, McMaster University, Hamilton, ON, Canada, 8University of Alberta, Edmonton, AB, Canada, 9Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, 10Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, 11Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 12Department of Rheumatology and Clinical Immunolgy, Charité University Hospital, Berlin, Germany, 13Rheumatology, Lapeyronie Hospital, Montpellier I university, Montpellier, France, 14Paris-Descartes University,, Paris, France, 15University of Manitoba, Winnipeg, MB, Canada, 16Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 17CaRE Arthritis, Edmonton, AB, Canada, 18CARE Arthritis, Edmonton, AB, Canada

    Background/Purpose: While, a Treat-to-Target strategy (T2T), treating patients with rheumatoid arthritis (RA) towards a certain target (eg. clinical remission; T2T-REM), is highly recommended, several patients…
  • Abstract Number: 100 • 2017 Pediatric Rheumatology Symposium

    Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment

    Akaluck Thatayatikom1, Renee F Modica2, Daniel S. Hammenfors3, Natalie Jane Shiff1 and Melissa E Elder2, 1Pediatrics, University of Florida, Gainesville, FL, 2Department of Pediatrics, University of Florida, Gainesville, FL, 3Department of Rheumatology, Haukeland University Hospital, Bergen, Norway

    Background/Purpose:  Juvenile Sjögren’sSyndrome (jSS) is a rare systemic autoimmune disease affecting predominantly salivary glands (SG) in children who do not meet criteria for SLE or MCTD. Currently, no specific criteria for…
  • Abstract Number: 1977 • 2016 ACR/ARHP Annual Meeting

    Impact of Ultrasound in Treatment Decision of Rheumatoid Arthritis Assessed in Routine Clinical Practice

    César Sifuentes-Cantú1, Lina Saldarriaga-Rivera2, Ana Cecilia Lozada2, Irazu Contreras-Yañez3, Marwin Gutierrez4 and Virginia Pascual-Ramos5, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Division of musculoskeletal and rheumatic diseases, Instituto Nacional de Rehabilitación, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 4Instituto Nacional de Rehabilitación, Mexico, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Remission or low disease activity is the therapeutic target for rheumatoid arthritis (RA). There is a consistent body of evidence supporting the value of…
  • Abstract Number: 1446 • 2014 ACR/ARHP Annual Meeting

    Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness

    Kuljeet Bhamra1, Catherine Swales1, Matthew Seymour1, Catherine McClinton1 and Peter C. Taylor2, 1Nuffield Department of orthopaedics,rheumatology and musculosketal sciences, University of Oxford, Oxford, United Kingdom, 2NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom

    Background/Purpose The aim of the survey was to evaluate the impact of clinic-based musculoskeletal ultrasonography (MSUS) on diagnosis and management of cases seen in the…
  • Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting

    Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study

    James Dale1, Anne Stirling2, Iain B. McInnes1 and Duncan Porter3, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Gartnavel General Hospital, Glasgow, United Kingdom, 3Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom

    Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
  • Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting

    Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study

    Karine R. Luz1, Rita N.V. Furtado1, Marcelo M. Pinheiro2, Giovanna S. Petterle1 and Jamil Natour1, 1Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, 2Brazilian Registry of Spondyloarthritis, São Paulo, Brazil

    Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology